These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1349746)

  • 21. 5-HT3 receptor-independent inhibition of the depolarization-induced 86Rb efflux from human neuroblastoma cells, TE671, by ondansetron.
    Toral J; Hu W; Critchett D; Solomon AJ; Barrett JE; Sokol PT; Ziai MR
    J Pharm Pharmacol; 1995 Jul; 47(7):618-22. PubMed ID: 8568632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New anxiolytics in development.
    Mosconi M; Chiamulera C; Recchia G
    Int J Clin Pharmacol Res; 1993; 13(6):331-44. PubMed ID: 7916335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential.
    Greenshaw AJ
    Trends Pharmacol Sci; 1993 Jul; 14(7):265-70. PubMed ID: 8105596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anxiolytic-like effect of way-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience.
    Canto-de-Souza A; Luiz Nunes-de-Souza R; Rodgers RJ
    Brain Res; 2002 Feb; 928(1-2):50-9. PubMed ID: 11844471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity.
    Alvarez-Guerra M; d'Alché-Birée F; Wolf WA; Vargas F; Dib M; Garay RP
    Psychopharmacology (Berl); 2000 Jan; 147(4):412-7. PubMed ID: 10672635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerance to acute anxiolysis but no withdrawal anxiogenesis in mice treated chronically with 5-HT1A receptor antagonist, WAY 100635.
    Cao BJ; Rodgers RJ
    Neurosci Biobehav Rev; 1998; 23(2):247-57. PubMed ID: 9884117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clozapine's antipsychotic effects do not depend on blockade of 5-HT3 receptors.
    Squires RF; Saederup E
    Neurochem Res; 1999 May; 24(5):659-67. PubMed ID: 10344595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
    Nakamura K; Kurasawa M
    Eur J Pharmacol; 2001 May; 420(1):33-43. PubMed ID: 11412837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anxiolytic effects of CCK-B antagonists.
    Costall B; Domeney AM; Hughes J; Kelly ME; Naylor RJ; Woodruff GN
    Neuropeptides; 1991 Jul; 19 Suppl():65-73. PubMed ID: 1679211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes.
    Gleeson S; Ahlers ST; Mansbach RS; Foust JM; Barrett JE
    J Pharmacol Exp Ther; 1989 Sep; 250(3):809-17. PubMed ID: 2476547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carboxylic acids: novel 5-HT3 receptor antagonists with anxiolytic-like activity in rodent behavioral models.
    Mahesh R; Dhar AK; Jindal A; Bhatt S
    Can J Physiol Pharmacol; 2013 Oct; 91(10):848-54. PubMed ID: 24144056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions.
    Barrett JE; Vanover KE
    Psychopharmacology (Berl); 1993; 112(1):1-12. PubMed ID: 7870996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Central action of 5-HT3 receptor ligands in the regulation of sleep-wakefulness and raphe neuronal activity in the rat.
    Adrien J; Tissier MH; Lanfumey L; Haj-Dahmane S; Jolas T; Franc B; Hamon M
    Neuropharmacology; 1992 Jun; 31(6):519-29. PubMed ID: 1407392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of ondansetron (GR38032F) in rats and mice treated subchronically with diazepam.
    Costall B; Jones BJ; Kelly ME; Naylor RJ; Oakley NR; Onaivi ES; Tyers MB
    Pharmacol Biochem Behav; 1989 Dec; 34(4):769-78. PubMed ID: 2576143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist.
    Jones BJ; Costall B; Domeney AM; Kelly ME; Naylor RJ; Oakley NR; Tyers MB
    Br J Pharmacol; 1988 Apr; 93(4):985-93. PubMed ID: 2898961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents.
    Dekeyne A; Brocco M; Adhumeau A; Gobert A; Millan MJ
    Psychopharmacology (Berl); 2000 Sep; 152(1):55-66. PubMed ID: 11041316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests.
    Jastrzębska-Więsek M; Siwek A; Partyka A; Kubacka M; Mogilski S; Wasik A; Kołaczkowski M; Wesołowska A
    Neuropharmacology; 2014 Oct; 85():253-62. PubMed ID: 24905144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The interaction of R(+)- and S(-)-zacopride with PCPA to modify rodent aversive behaviour.
    Barnes NM; Costall B; Ge J; Kelly ME; Naylor RJ
    Eur J Pharmacol; 1992 Jul; 218(1):15-25. PubMed ID: 1356806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-HT1A receptor full and partial agonists and 5-HT2C (but not 5-HT3) receptor antagonists increase rates of punished responding in rats.
    Cervo L; Samanin R
    Pharmacol Biochem Behav; 1995 Dec; 52(4):671-6. PubMed ID: 8587903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists.
    Tyers MB
    Therapie; 1991; 46(6):431-5. PubMed ID: 1840227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.